EWM
REGN icon

Elite Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Elite Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-23
Closed -$6K – 598
2013
Q4 		$6K Buy
+23
New +$6.62K ﹤0.01% 432

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Elite Wealth Management's REGN Position: Q1 2014 in Review

Elite Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2014, closing a stake of 23 shares — an estimated $6K sold.

Elite Wealth Management first reported a position in REGN in Q4 2013 and held it in 1 quarter. The position peaked at $6K in Q4 2013. 452 funds tracked by Wall St. Rank hold REGN as of Q1 2014.

  • Elite Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Elite Wealth Management sold 23 Regeneron Pharmaceuticals shares in Q1 2014, an estimated $6K.
  • Elite Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Elite Wealth Management's Regeneron Pharmaceuticals position peaked at $6K in Q4 2013.
  • 452 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2014.

Based on Elite Wealth Management's 13F filing for Q1 2014, filed 23 Nov 2016.